I really meant it for the exus markets because what countries are going to start to experience over that time frame is fewer drug launches or delayed drug launches, particularly these eight markets that are the target of the MFN uh MFN agreements. And I think what'll happen is that will increase political pressure on these leaders to really reform their innovation environments. As you know, in most of these countries, there are multiple ways that innovation is improperly rewarded.And this MFN agreement is n ...